We are a science-led global healthcare company on a mission: we want to help people do more, feel better, live longer. Today there are still millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments. At GSK we want to change this. We have three world-leading businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We are committed to widening access to our products, so more people can benefit, no matter where they live in the world or what they can afford to pay.

Company Growth (employees)
Brentford, GB
Size (employees)
101,192 (est)
GlaxoSmithKline was founded in 2001 and is headquartered in Brentford, GB

Key People at GlaxoSmithKline

Andrew Philip Witty

Andrew Philip Witty

Emma Walmsley

Emma Walmsley

CEO of GSK Consumer Healthcare
Simon Dingemans

Simon Dingemans

David Redfern

David Redfern

Dan Troy

Dan Troy

General Counsel
Philip Thomson

Philip Thomson

SVP Global Communications & Government Affairs

GlaxoSmithKline Office Locations

GlaxoSmithKline has offices in Brentford, Tirana, Boudouaou Est, Buenos Aires and in 153 other locations
Brentford, GB (HQ)
980 Great West Road
Wavre, BE
Site Apollo, Pascal Avenue, 2 4 6
Minsk, BY
Office 905, 7a Voronianskogo Street
Bangladesh, IN
Road # 138, Gulshan # 1, Dhaka 1212
Baku, AZ
96 Nizami Street
Wien, AT
Euro Plaza, Gebäude I, 4. Stock, Wagenseilgasse 3
Boronia, AU
1061 Mountain Highway
Yerevan, AM
7 Baghramian Avenue, Flat 3
Buenos Aires, AR
Glaxo Smith Kline Argentina Sa, Carlos Casares 3690, Victoria
Boudouaou Est, DZ
Boumerdes, 35 400
Tirana, AL
Str. Barrikadave No. 118

GlaxoSmithKline Metrics

GlaxoSmithKline Financial Metrics

Revenue (2016)

£27.9 b

Revenue growth (2015-16), %


Gross profit

£18.6 b

Gross profit margin (2016), %


Net income (2016)

£1.1 b

Market capitalization (28-Apr-2017)

$99.5 b

Closing share price (28-Apr-2017)


Cash (31-Dec-2015)

£5.8 b
GlaxoSmithKline's current market capitalization is $99.5 b.
GlaxoSmithKline's revenue was reported to be £27.9 b in FY, 2016 which is a 17% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


£26.5 b£23 b£23.9 b£27.9 b

Revenue growth, %


Cost of goods sold

£8.6 b£7.3 b£8.9 b£9.3 b

Gross profit

£17.9 b£15.7 b£15.1 b£18.6 b

Gross profit Margin, %


Sales and marketing expense

£8.5 b£8.2 b£9.2 b£9.4 b

R&D expense

£3.9 b£3.5 b£3.6 b£3.6 b

Operating expense total

£10.9 b£12.1 b£12.8 b£13 b

Interest expense

£767 m£727 m£757 m£736 m

Interest income

£104 m£68 m£104 m£72 m

Pre tax profit

£6.6 b£3 b£10.5 b£1.9 b

Income tax expense

£1 b£137 m£2.2 b£877 m

Net Income

£5.6 b£2.8 b£8.4 b£1.1 b
FY, 2013FY, 2014FY, 2015


£5.5 b£4.3 b£5.8 b

Accounts Receivable

£4 b£3.6 b£3.9 b

Current Assets

£15.2 b£14.7 b£16.6 b


£13.4 b£13.9 b£15 b


£13.5 b£12 b£21.8 b

Total Assets

£42.1 b£40.7 b£53.4 b

Accounts Payable

£2.7 b£2.8 b£3.1 b

Current Liabilities

£13.7 b£13.3 b£13.4 b

Retained Earnings

£1.9 b(£1.1 b)£4.6 b

Total Equity

£7 b£4.3 b£5.1 b

Financial Leverage

6 x9.5 x10.5 x
FY, 2013FY, 2014FY, 2015

Cash From Operating Activities

£2.6 b£5.2 b£7.2 b

Cash From Financing Activities

(£6.3 b)(£5.4 b)(£7.1 b)

Income Taxes Paid

(£1 b)(£137 m)(£2.2 b)

GlaxoSmithKline Operating Metrics

GlaxoSmithKline's Volume of Medicines Produced was reported to be 2 b in FY, 2016
FY, 2014FY, 2015FY, 2016

NME in Late-stage Development


Ongoing Phase III Programs


Drugs Approved by FDA


Projects in R&D Pipeline


Vaccines Delivered

833 m

Consumer Healthcare Products Produced

5 b

Volume of Medicines Produced

2 b

GlaxoSmithKline Market Value History

GlaxoSmithKline Revenue Breakdown

GlaxoSmithKline Median Salaries

Source: 173 public H-1B filings from GlaxoSmithKline

GlaxoSmithKline Online Presence

GlaxoSmithKline Company Life

You may also be interested in